Remote Monitoring & Chronic Care

Octagos completes the cardiac implantable device monitoring set alongside Implicity and PaceMate, and it takes the third distinct position. Implicity clears algorithms and publishes their sensitivity. PaceMate sells operations, billing and a security certification. Octagos sells the model and the humans reviewing it as a single indivisible product, which it brands the Two Brain Approach. Atlas AI is the engine. It reads incoming device transmissions, filters non actionable alerts, prioritises what needs clinical attention and surfaces findings across a clinic's population, with the company reporting clinic noise reduced by more than 25 percent and reports delivered at 98 percent accuracy. The company is explicit that automation alone is not enough, and pairs the model with United States based specialists certified by the International Board of Heart Rhythm Examiners who review alongside it. Its framing of the boundary is unusually direct: clinical teams review the model's output rather than handing judgment over to it. The headline performance claim is the highest in this segment and is attributed to a study the company describes as published in the Journal of the American College of Cardiology, reporting more than 99 percent accuracy, sensitivity and specificity for the combined system. Those figures describe the model and its human reviewers together rather than the algorithm alone, which the company does not obscure but which a reader comparing against Implicity's algorithm only sensitivity of 98.3 percent should hold in mind. Scope extends past implanted devices to ambulatory electrocardiographic monitoring, addressing a real fragmentation problem since those two workflows usually sit in separate systems. Around the platform sit a clinic mobile application, bidirectional integrations with major record systems including a named ambulatory system, automated billing and reporting, and a patient connectivity team whose job is keeping patients transmitting at all. Ask Atlas is the most distinctive recent capability. It lets a device clinic query its own monitoring data in plain language across patient care, operations, research and revenue, with the company's own examples running from which patients are overdue for a remote check to showing every actionable red alert this month. That is a natural language interface over a clinic's own population, and no other record in this segment offers it. Based in Houston, Texas, with a cardiac electrophysiologist serving as chief medical and compliance officer. The platform became available through the Microsoft commercial marketplace in February 2026. One thing a reader should weigh. Much of the comparative material about competitors in this segment is published by Octagos itself, which is useful and interested at the same time.

PaceMate is the United States counterpart to Implicity and the pair should be read together. Both aggregate cardiac implantable electronic device data across manufacturers and triage the resulting alert volume. Implicity approaches it as a regulated algorithm company with three cleared models and published sensitivity figures. PaceMate approaches it as a data and operations platform, and its strongest differentiators are commercial and security rather than clinical. PaceMateLIVE aggregates discrete device data, described as including serial numbers rather than only the summary fields, and pairs it with electronic health record data in one platform. The scope is broader than implanted devices alone: the company describes covering implantable cardiac devices, ambulatory event monitoring, heart failure monitoring and consumer electrocardiograms in a single platform, and a 2023 collaboration with AliveCor, separately indexed here, brought that consumer layer in by integrating the KardiaPro platform to capture and triage data from six lead and single lead consumer devices. Following one patient from a consumer wearable through to an implanted device on one platform is a genuine coverage claim. The billing capability is unusually developed and is stated with more specificity than most vendors offer about anything. Every remote monitoring procedure code is handled automatically, 31 day and 91 day billing cycle tracking is built into the workflow, missed charge recovery runs continuously, code updates are maintained by the vendor, and billing data synchronises bidirectionally with Epic, Oracle Health and athenahealth. Reported outcomes include 98 percent of manual billing entry eliminated and 75 percent average billing capture within 90 days of go live. In June 2026 the company achieved ISO/IEC 27001:2022 certification from a named accredited certification body, publishing the certificate number, and argued publicly that this goes beyond the health privacy statute compliance and service organisation control attestations its named competitors rely on. That is the most substantive security credential held by any vendor built in this session. Evidence includes work presented at HRS 2026 reporting a 61 percent reduction in alert burden, with a named academic cardiologist presenting, and a published case study describing electronic health record integration at a health system and clinician training taking around 15 minutes. Founded in 2015 and based in Clearwater, Florida, led by chief executive Tripp Higgins. One thing a reader should weigh. A competitor's published comparison characterises the platform as built for one manufacturer's devices and describes limitations in multi manufacturer populations, which conflicts with the company's own all device types claim. That is an interested source and the discrepancy is recorded rather than resolved.

Implicity solves a problem the two neighbouring cardiac records do not have. iRhythm and AliveCor collect their own data from their own hardware. Implicity collects nothing: it takes the data cardiac implantable electronic devices already transmit, from every manufacturer, and applies models to decide which of it a clinician should actually look at. The underlying problem is alert burden. Pacemakers, defibrillators, resynchronisation devices and insertable cardiac monitors transmit continuously, each manufacturer uses its own portal and format, and a clinic following several hundred patients receives a volume of notifications in which the clinically important events are buried. Published work cited by the company puts atrial arrhythmia episodes at up to 51 percent of the events clinicians are expected to review. The platform aggregates, normalises and standardises data from Abbott, Biotronik, Boston Scientific, Medtronic and Microport into one interface, working from raw discrete manufacturer data rather than the summary documents the portals produce. Three cleared algorithms sit on top. The ILR ECG Analyzer received FDA 510(k) clearance in 2021 for assessing arrhythmias in insertable cardiac monitor data, initially Medtronic devices, and the company reports it reduces false positives by 79 percent while maintaining 99 percent sensitivity. An atrial fibrillation alert management algorithm filters device notifications and classifies episodes against European Society of Cardiology recommendations, with a retrospective study of more than 4,000 patients across four manufacturers published in the Cardiovascular Digital Health Journal, and a reported 85 percent reduction in unnecessary alerts. SignalHF analyses physiological trends including thoracic impedance, nighttime heart rate and activity to identify early signs of cardiac decompensation, and the company describes it as the first algorithm of its kind cleared and compatible across manufacturers. Evidence presented at EHRA 2026 is unusually candid. Across implantable cardiac monitor generations the algorithm held sensitivity at 98.3 percent in devices with their own onboard artificial intelligence and 94.3 percent in those without, with specificity of 61.6 and 75.6 percent respectively and positive predictive value around 74 percent in both. Publishing specificity in the sixties alongside high sensitivity is a vendor showing the actual shape of the tradeoff. Co founded by cardiac electrophysiologist Arnaud Rosier, with headquarters in Paris and Cambridge, Massachusetts. The company reports more than 110,000 patients monitored across over 250 medical facilities in the United States and Europe, and states access to the French government's Health Data Hub, described as one of the world's largest heart disease patient databases, for model development.

AliveCor is the natural counterpart to iRhythm and the two divide cardiac artificial intelligence between them along a clean line. iRhythm records continuously for up to 14 days and answers what rhythm this patient has over time. AliveCor takes a recording lasting seconds and answers what is happening now, which is a different clinical question and a different regulatory problem. The company began in consumer grade personal electrocardiography, with the KardiaMobile family placing FDA cleared single and six lead recording in a patient's hand, and it describes itself as the leading provider of cleared personal electrocardiogram devices. The record's centre of gravity has since moved toward the clinic. Kardia 12L, launched June 2024, is the current flagship and the technical claim behind it is unusual. A single cable and five electrodes acquire eight diagnostic bandwidth leads, from which KAI 12L, the artificial intelligence powering the system, reconstructs and interprets a full 12 lead study. That reduced leadset design is why the device is pocket sized, and it is also why the intelligence is doing something a conventional machine does not have to: inferring what the missing leads would show. The cleared scope is the largest of any single artificial intelligence system in this index. KAI 12L launched with 35 cardiac determinations, 14 arrhythmias and 21 morphologies, and a further clearance in January 2026 added short PR interval, atrial bigeminy, ventricular bigeminy, left axis deviation and right axis deviation, bringing the total to 39. It is described as the first cleared artificial intelligence able to detect a heart attack from a reduced leadset, covering acute myocardial infarction and common forms of cardiac ischemia. The system is built on multiple deep neural network algorithms trained and validated on more than 1.75 million electrocardiograms from leading United States medical centres. Deployment and evidence are both concrete. Since launch the system has reached more than 250 clinical practices in the United States and expanded into India, Australia and New Zealand, with European regulatory review ongoing. The company reports use on tens of thousands of patients and identification of more than 4,000 cases of myocardial infarction and ischemia. A peer reviewed study in Heart Rhythm O2 found the system reduced electrocardiogram acquisition time by 29 percent. In 2025 the Centers for Medicare and Medicaid Services approved payment in hospital outpatient settings. Based in Mountain View, California, led by chief executive Priya Abani, and named to the inaugural TIME World's Top Health Tech Companies list in 2025. An InstantQT product for remote point of care recording launched in Europe in July 2024.

iRhythm is the largest absence this index had in remote monitoring, and it is one of the few companies anywhere whose artificial intelligence claim rests on a landmark paper in a top tier medical journal. The product is a service rather than a device sold alone. A Zio adhesive patch records continuous single lead electrocardiography for up to 14 days, the patient returns it, and the recording passes through a deep learned algorithm before qualified cardiac technicians verify the output and a physician receives a report. The company is explicit that artificial intelligence and human review operate together, describing the algorithm as verified by technicians rather than as autonomous, and the reported result is 99 percent physician agreement with the end of wear report. The scale of the training data is the moat and the company states it plainly: more than 750 million hours of curated heartbeat data, described as the largest repository of labelled electrocardiographic patient data in the world. That is the direct consequence of running a service rather than selling a device, because every patch returned is another labelled recording, and it is why average rhythm detection sensitivity is stated as having improved 21 percent since the algorithm's creation in 2010, moving from machine learned to deep learned methods. The scientific anchor is Hannun and colleagues in Nature Medicine in 2019, demonstrating a deep neural network classifying a broad range of arrhythmias at diagnostic performance comparable to cardiologists. The company describes more than 100 original research manuscripts covering the service, including comparative effectiveness work in the American Heart Journal and a Medicare beneficiary utilisation study, and it publishes citations rather than adjectives. Regulatory coverage is broad: 510(k) clearance in the United States, CE marking, UKCA marking and Japanese approval, with the deep learned algorithm available in the United States, European Union, Switzerland, United Kingdom and Japan. Thirteen arrhythmia classes are detected and the company states these were included in the procedure code validation process. A separate wrist worn product, the Zio Watch, was cleared with Verily under the ZEUS software for detecting atrial fibrillation and characterising its burden over time. Around the analysis sits a provider portal, electronic health record integration and a patient application. The company is publicly traded and led by chief executive Quentin Blackford. One thing a reader should weigh. The deep learned algorithm is not available in every market where the devices are sold, which the company discloses in a footnote, so the artificial intelligence a buyer is assessing may not be the artificial intelligence they receive.

Biofourmis monitors patients at home and tries to detect deterioration before it becomes an admission. The Biovitals analytics engine ingests continuous signals from clinical grade wearables, builds a personalised physiological baseline for the individual rather than comparing them to a population norm, and raises an alert when that person drifts from their own pattern. Biofourmis Care wraps that in a care at home offering for hospitals, health systems and payers spanning acute, post acute and chronic acuity, combining the algorithms with devices, in home service orchestration and virtual clinical teams. Biofourmis Connect applies the same monitoring apparatus to decentralised clinical trials for biopharma customers. BiovitalsHF, a heart failure product aimed at optimising medication dosing, received Breakthrough Device Designation in 2021. The corporate history is turbulent and a reader should have it. Founded in 2015 and originally based in Singapore, the company moved its headquarters to the United States in 2019 with about 60 employees and grew to roughly 650 including two acquisitions. It raised in the region of 460 million dollars across six rounds, including 100 million in 2020 and a 300 million dollar round in 2022 that valued it at 1.3 billion, backed by SoftBank Vision Fund, General Atlantic, Openspace, Bessemer Venture Partners, Intel Capital and CVS Health. In July 2023 it cut 120 roles globally, about 15 percent of the company, and the founding chief executive stepped down a month later. In October 2024 it merged with CopilotIQ, a Nashville company running high frequency connected care for older adults with hypertension and diabetes using continuous biomarker data, behavioural analytics and nursing visits by licensed clinicians. The transaction was all stock, existing investors put close to 100 million dollars into the combined business, and CopilotIQ's chief executive David Koretz leads the combined entity. Biofourmis continues to be sold under its own name with its own product lines, so the change of control does not alter how this record reads. Named customers include UCI Health, Lee Health, Community Health Network, Augusta University Health under a four year collaboration, and Orlando Health under a multi year agreement. A partnership with GE HealthCare announced in February 2024 was intended to extend that manufacturer's patient monitoring reach from the hospital into the home. Headquartered in Needham, Massachusetts. Two things a reader should weigh. A dedicated pass located no company announcement of any kind after the October 2024 merger, and the corporate website, while live and carrying a current copyright, still displays placeholder Latin text in its main navigation menus. Neither fact establishes anything about the health of the business, and both are things a buyer would want to ask about directly. And no pricing of any kind was located.

Lightbeam Health Solutions assembles a value based care operating system largely by acquisition, and the pieces it bought explain what it is. The core platform aggregates data from many sources, normalises and represents it, mines it for care gaps, performs risk stratification and returns the result to providers at the point of care. Around that core sit three purchased businesses. CareSignal, acquired in November 2021, contributes what the company brands Deviceless Remote Patient Monitoring, a text message and telephone based monitoring approach with condition specific programmes. Jvion, whose operating assets were acquired in 2022, contributes prescriptive analytics that combine clinical, socioeconomic, environmental and behavioural data to identify patients on a trajectory toward becoming high risk and to indicate which interventions would change that trajectory, together with social determinants and health equity capability. Syntax Health, acquired in December 2025, contributes contract modelling, incentive design and actuarial services, which extends the company from measuring performance under a risk contract to helping design the contract itself. The evidence base is stronger than most records in this lane and it comes from outside the company. The remote monitoring product was ranked first in its category in a research firm's 2024 customer survey, a ranking derived from client responses rather than vendor submissions. Recognition as a Microsoft healthcare and life sciences partner of the year followed in 2025, and the care orchestration suite is transactable through that vendor's cloud marketplace. The company states that in the 2022 performance year its accountable care organisation clients managed care for 1.1 million patients. Harris County Public Health is a named public sector customer of the monitoring product. Security certification is at the top tier of the healthcare assurance framework and carries a visible history, with initial certification in January 2022 and renewal at the risk based two year level in February 2024. A quality reporting capability supporting accountable care organisations migrating to fully electronic measure reporting is a concrete piece of interoperability work rather than a claim. Founded and led by Pat Cline, previously a long serving executive at an electronic health record company, and backed by Hearst and Primus Capital. Headquartered in the Dallas area. Two things a reader should weigh. The branded monitoring category is described as deviceless, and federal remote physiologic monitoring reimbursement generally requires data transmitted automatically from a medical device, so a buyer should establish directly whether a given programme is billable under those codes or is a clinically useful engagement programme funded another way. And no pricing of any kind was located.

Nanowear weaves the sensors into the clothing. SimpleSense is a gender neutral, size adjustable undergarment built from patented cloth based nanosensors, capturing electrophysiological, hemodynamic, acoustic, metabolic and activity signals simultaneously and time synchronously, and feeding a deep learning platform that turns them into diagnostics. The company describes capturing more than 100 million data points per patient per day across cardiac, pulmonary and circulatory biomarkers, and positions the garment as replacing several separate instruments a clinician would otherwise use in sequence. Regulatory standing is the strongest element and includes one clearance type that matters more than its number. Four United States clearances span 2016, 2020, 2021 and January 2024. The 2021 clearance was software only, establishing standalone artificial intelligence and deep learning algorithms as a medical device in their own right rather than as an accessory to hardware. The 2024 clearance covered a cuffless continuous blood pressure diagnostic built on a four decision tree algorithmic model, validated across three study arms with training and validation performed in independent geographies and in demographic populations described as mirroring the most recent national census. The company publishes its indication for use, which is rare enough in this index to be worth stating plainly, and a reader should compare it against the marketing. The published indication covers use at home or in a healthcare facility, under the direction of a licensed medical professional, to record, display and store two leads of electrocardiogram, respiration rate measured through thoracic impedance, heart sounds, and activity including posture. That is a narrower and more precise claim than a garment capturing 85 or more biomarkers and replacing a stethoscope, a Holter monitor, a capnograph and a blood pressure cuff. Both statements come from the company; the cleared one is the one that binds. A dedicated security page exists naming Amazon Web Services as the host and linking a privacy notice, which again is more than most vendors here provide. Founded in 2014 and headquartered in New York with research operations in Berkeley and University Park, led by co founder and chief executive Venk Varadan. Intellectual property spans 13 awarded and 12 pending patents covering the nanotechnology, sensor manufacturing, the wearable, the software platform, the ingestion pipeline and the algorithms. Reported funding totals vary widely across sources and the chief executive has publicly stepped back from pursuing venture capital, so no figure is asserted here. Recent activity includes a licensing and data partnership ingesting continuous glucose readings from Dexcom and an integration initiative with blood collection patches. No pricing of any kind was located.

Aloe Care Health rebuilt the medical alert pendant around voice and sensors. Its patented Smart Hub sits in the home carrying motion, temperature and air quality sensors, connects over cellular without requiring home broadband, and can be triggered three ways: a large central button that doubles as a motion activated nightlight, a wearable care button, or simply saying the word emergency aloud. Yes and no buttons let an older adult answer an operator or a family member without finding a phone. A Mobile Companion extends coverage outside the home with fall detection, location and caregiver speed dial, and a caregiver application connects an unlimited circle of family members. Behind it sits a professional emergency response centre available at all hours. The design choices are deliberate and worth naming. There are no cameras, which the company states plainly as a differentiator in a category increasingly built on them. Connectivity is cellular first with battery backup, addressing the failure mode where an older adult's router quietly stops working. Fall detection sensitivity is user adjustable. And the fall detection claim carries an explicit published caveat that it cannot detect every fall, printed beside the feature rather than buried, which is a candour almost nothing else in this index matches on a safety critical function. Monitoring extends past emergencies into ambient wellbeing. The hub watches for unusual movement patterns, inactivity, dangerous air quality, temperature extremes and power outages, notifying caregivers and emergency personnel automatically when something is out of the ordinary. Commercially it is unusually legible because it is a consumer product. Subscriptions are published from around 40 dollars per month across named tiers covering the hub alone, the hub with mobile coverage, and a full package, with a separate one time hardware cost. Roughly 12.1 million dollars was raised across two rounds in 2020 and 2021. In April 2026 Arlo Technologies completed its acquisition of the company, folding the platform into its own subscription services business and describing it as an artificial intelligence powered medical alert and fall prevention platform. The brand and product line continue under their own name, which is why this is indexed separately, though a reader should note that the artificial intelligence framing is considerably stronger in the acquirer's announcement than in the product's own description, which emphasises voice activation, sensors and staffed emergency response. A dedicated pass located no clinical study, no security attestation and no data handling statement.

Electronic Caregiver puts an animated character in an older adult's living room and asks it to do the work a care visit would. Addison Care is a three dimensional avatar running on a tablet, combining conversational speech with real time vitals capture from connected devices, medication management, cognitive engagement exercises, emergency response and escalation into the company's own telecare operation. The avatar is the deliberate design choice: the company spent years arguing that a face and a conversation drive adherence in a way a voice assistant or a portal does not. The underlying stack is described in unusual breadth, spanning augmented reality interfaces, conversational speech, machine learning, visual sensing, biomechanical analytics developed with a state university's health and aging laboratories, record system integration and the connected hardware itself. Large language model integration is explicit, with the platform stated to be integrated with OpenAI's ChatGPT, which is a base model disclosure almost no vendor in this index provides. The commercial position rests on reimbursement rather than on a licence fee. Addison Care launched in June 2025 shipping to Medicare patients under established remote patient monitoring and chronic care management codes, beginning with four clinical locations and a large Alaskan primary care group serving rural patients hours from emergency care. Other routes include a New Mexico developmental disability waiver programme for remote support technology, Medicaid, commercial cover and private pay, alongside national payer taxonomy approvals. More than 100 pilot deployments are claimed across multiple verticals, and a home care franchise partnership markets a hybrid model combining in person visits with continuous virtual care. The company is not only software. It operates a full telecare function with nursing and clinical support, round the clock emergency response, physician on demand, national device fulfilment and device lifecycle management. Its own chief executive frames that operational depth rather than the artificial intelligence as the real barrier to entry, which is an honest description of what the business is. Based in Las Cruces, New Mexico, previously trading as SameDay Security, led by founder Anthony Dohrmann. Roughly 42.5 million dollars was raised in a round with a warrant exercise, following 35 million dollars in private equity in 2019. Outcome figures circulate in partner directories, including a 47 percent readmission reduction and a 70 percent expansion of inpatient capacity through hospital at home, with no method, sample or site attached. No pricing, security attestation or trust centre was located.

Vivalink sells the sensing and data layer that other companies build monitoring products on. Its Biometrics Data Platform combines medical grade reusable wearables with edge networking, cloud data services and a development kit, so a digital health company, a hospital at home programme or a clinical trial sponsor can capture continuous physiology without building the hardware or the pipeline. Sensors cover a multi function cardiac electrocardiography patch, a clinical temperature monitor, oxygen saturation and blood pressure, and the platform additionally ingests third party devices including glucose monitors and pulse oximeters from established manufacturers. The technical lineage is genuine. The company introduced a breathable thin film substrate with integrated circuits and sensors in 2014, developed in collaboration with Google's advanced technology group and launched commercially as a digital tattoo, and that substrate underpins the current sensor family. Regulatory and standards posture is the strongest part of this record and is enumerated rather than gestured at. Sensors carry clearance in the United States, the European Union and China. The platform is stated to comply with United States health privacy law, European data protection law, the federal rule governing electronic records and signatures in regulated research, and a stack of device standards covering quality management, medical device software lifecycle, risk management and biocompatibility, alongside the international information security management standard. Very few vendors in this index name an information security certification at all, and fewer still list the software lifecycle and biocompatibility standards that a skin adhering connected device actually needs. The business is enablement rather than end user software. More than 400 customers are claimed with brand reach across 116 countries, and named applications include ambulatory cardiac monitoring, hospital at home and decentralised clinical trials, with a partnership placing the technology inside a global trial infrastructure provider. Research use includes a longitudinal atrial fibrillation study of up to 3,000 subjects, a chronic obstructive pulmonary disease progression study, and sleep research. Founded in 2014 by Jiang Li and based in Campbell, California, operating as VivaLNK, Inc. Funding is poorly documented in public sources and the figures that circulate appear inconsistent with the company's stated commercial reach, so no total is asserted here. Two things a reader should weigh. This is closer to infrastructure than most records in this index, since much of the value is capturing and delivering data rather than interpreting it, and the clinical application is frequently the customer's. And no pricing of any kind was located.

Current Health enables hospital at home. Its platform combines a continuous vital signs wearable with aggregated data from other remote monitoring devices and patient reported information, presenting a picture of a patient's trajectory to a clinical team that is not in the room. Around that sits the operational machinery that makes acute care at home actually work: device kits, in home installation, patient onboarding, virtual visits and care coordination. Oncology at home is addressed as a distinct programme alongside general acute and chronic care. The wearable received United States Class II clearance in February 2019 as an artificial intelligence powered device, monitoring vital signs continuously and delivering patient specific alerts, with further machine learning related clearance reported in 2021. The company was founded in 2014 in Edinburgh by Christopher McGhee after watching his grandmother manage chronic obstructive pulmonary disease, dementia and congestive heart failure at home, and is now headquartered in Boston. Deployment reach is the strongest fact on this record. The company states that more than one third of all patients in the United States who have had a hospital at home experience were cared for through its platform, with more than 70,000 patients across care models. Named health system partners include Mass General Brigham, Geisinger, UC Davis, Atrium Health, Baptist Health, UMass Memorial Health, Virtua Health and OSF HealthCare. A partnership with Cardinal Health's Velocare handles last mile fulfilment, installation and retrieval of in home monitoring kits. Ownership has moved twice and a reader should understand both moves. Best Buy acquired the company in October 2021 for 400 million dollars and sold it back to founder Christopher McGhee in June 2025, exiting care at home entirely and recording 109 million dollars of restructuring charges followed by a further 192 million dollar impairment as it wound down remaining health system relationships. The company is independent again under its original founder. The reason for that exit is the most important commercial fact in this record and it is not about the technology. Acute hospital at home in the United States is paid for through a federal waiver whose renewal has repeatedly been caught in budget negotiations, and that uncertainty was cited directly by the acquirer as why adoption scaled more slowly than expected. Roughly 400 hospitals across 142 systems in 30 states were approved under the waiver as of mid 2025, against 20 programmes before it existed. Any buyer evaluating this category is underwriting a reimbursement policy as much as a product. Two dedicated passes located no pricing, no security attestation, no data handling statement and no peer reviewed outcome study.

Sibel Health makes soft, flexible sensors that stick to skin and monitor vital signs without a single cable. The ANNE platform pairs a chest sensor capturing electrocardiography, heart rate, respiratory rate, skin temperature, body position and activity with a limb sensor capturing photoplethysmography, oxygen saturation, pulse rate and temperature, feeding an application and central hub that display, alarm and support multi patient monitoring. A Northwestern University spinout founded in 2018, the company sits in the Chicago area with offices in San Diego and Seoul and operates in more than 20 countries. The population coverage is the widest in this index and is backed by separate clearances rather than by claim. ANNE Pediatrics is indicated for neonates including those born extremely premature. ANNE One covers adolescents from 12 and adults, in hospital and at home. ANNE Maternal, cleared in April 2026, is described as the first fully wireless platform for simultaneous maternal and fetal monitoring through labour, delivery and the postpartum period, streaming maternal vital signs alongside fetal heart rate and uterine contraction detection. A separate cough sensor, Aria, has been accepted into a federal qualification programme as a drug development tool, and a Discovery platform serves pharmaceutical clinical trials. Regulatory standing is extensive: at least eight United States clearances, with a seventh announced in March 2025 covering alarms, alerts and a central station, and European Class IIb certification under the current medical device regulation granted in June 2026. Two things distinguish this record from its peers. The sensors are cleared under an open medical device communication standard rather than a proprietary network, and the European certification was announced specifically as the first wireless wearable monitoring platform certified to key interoperability standards. A major patient monitoring manufacturer, which is also an investor and co development partner, cites that open standard as the reason for the collaboration, and the two were selected by the Capital Region of Denmark to deploy across Copenhagen hospitals. The second is bias. The company states it has validated the accuracy of its pulse oximeter across a wide range of skin tones, which addresses the single most documented measurement failure in physiologic monitoring, and that work sits alongside deployments in India, Pakistan, Nigeria and Rwanda with a United Kingdom university research unit, supported by a 17.5 million dollar philanthropic grant aimed at low resource settings. Series C financing reached 39 million dollars by October 2025 with total funding above 63 million, led by existing investors. Two dedicated passes located no pricing of any kind, no information security certification and no trust centre, and the published privacy policy is minimal.

Huma sells a regulated platform that other organisations configure into their own clinical software. The Huma Cloud Platform is a disease agnostic and device agnostic software as a medical device, cleared as a configurable framework rather than as a single product, so a hospital, national health system or pharmaceutical sponsor can assemble a regulated disease management tool from pre built modules with no code and deploy it in weeks rather than running a multi year regulatory programme of its own. Partners inherit the clearance. That clearance is the most extensive in this index. The platform holds simultaneous status across six jurisdictions: United States Class II under the 510(k) route, European Union Class IIb under the current medical device regulation, United Kingdom Class IIb registration, Australian, Saudi and Indian approvals, with a Health Canada Class II licence added subsequently. The United States clearance permits monitoring patients of any age with any condition, explicitly including paediatrics and pregnancy, and the platform is regulated to host artificial intelligence and machine learning models rather than only fixed logic. Five layers sit on that base: remote patient monitoring and companion apps, decentralised clinical trials, Hi Scribe for generative clinical documentation, an agentic layer marketed as Huma Intelligence, and direct to consumer virtual care. A software development kit lets partners embed functionality into their own products, and the hosting framework is described as cloud agnostic. Scale is substantial and geographically wide. Company material has reported more than 3,000 hospitals and clinics, over 1.8 million active users in care delivery and more than 650,000 research participants, with the platform used to build software across more than 70 countries. Published case work includes an emergency department triage deployment in a London hospital, a decade long oncology real world evidence study, a lung cancer screening programme validating a risk model that has become part of a national screening blueprint in Germany, a non interventional insomnia study across Germany and Austria, and a kidney and diabetes research programme that recruited 4,500 patients a year ahead of schedule. Huma Therapeutics Limited is based in London with New York operations and is led by founder and chief executive Dan Vahdat. Series D financing closed in July 2024 taking total funding past 80 million dollars, with investors including the venture arm of a major pharmaceutical group. Two things a reader should hold. The strongest asset here is regulatory and architectural rather than algorithmic: the platform's distinguishing property is that it is cleared and configurable, and much of the artificial intelligence running on it belongs to partners. And two dedicated passes located no pricing of any kind, no information security certification and no customer facing trust centre, with the clearest account of data handling appearing in a clinical trial protocol rather than in anything a prospective buyer would find.

BioIntelliSense replaces the four hourly vital signs check with a coin sized sensor worn on the upper left chest. The BioButton captures heart rate, respiratory rate, skin temperature, body position and activity continuously, generating thousands of measurements per patient per day, which flow through BioHub wireless gateways to BioCloud analytics and surface in the BioDashboard clinical intelligence system. Two device variants exist: a single patient disposable and a rechargeable multi patient version for inpatient use, the latter cleared alongside the dashboard in October 2024. An earlier acquisition brought in a separately cleared clinical intelligence platform. The design decision that defines the product is exception management. Rather than streaming waveforms to a central station, the system holds personalised trending thresholds per patient and notifies only on deviation, which is what allows one clinician to watch hundreds of patients at once. The company publishes the two numbers that make that claim assessable: fewer than one notification per patient per day, and clinician engagement with those notifications at 99.71 percent. Alert fatigue is the recognised failure mode of continuous monitoring, and publishing both the volume and the response rate is the pair of figures that shows alerts are being acted on rather than dismissed. Evidence is genuine and includes an outcome study. Peer reviewed research in the Journal of Clinical Medicine covered nearly 12,000 hospitalised patients across the medical surgical units of two hospitals over 15 months, reporting reduced length of stay, low alert notification rates and earlier intervention on deterioration events. Separately, an independent academic validation published on the device's activity and position detection in children reported sensitivity and specificity figures the company did not commission, including results that are candidly mixed. More than 400,000 patients had been monitored as of October 2025. Deployment includes a full system reference rather than a pilot. Houston Methodist completed expansion across all 2,653 non intensive care beds at its eight hospitals, with a centralised command centre staffed by a multidisciplinary team. Intermountain Health and TriHealth are also named. The commercial argument is built on the alternative rather than on the product, and is unusually well sourced: continuous telemetry costs hospitals up to 1,400 dollars per patient per day, one review found 22.3 percent of patients inappropriately assigned to telemetry at admission with over half monitored longer than guidelines recommend, and a 2024 multicentre study attributed 33 percent of patient sleep interruptions to routine vital sign checks. Based in Denver. Two dedicated passes located no pricing of any kind, no security attestation, no trust centre and no data handling statement.

Vayyar Care detects falls and monitors movement using 4D imaging radar, with no camera and nothing worn. A ceiling or wall mounted sensor builds a point cloud of the room and machine learning classifies what is in it: falls both major and minor, room presence, mobility, time at rest and bathroom visits. Low power radio waves pass through obstructions, so the sensor keeps working through shower curtains and steam and in any lighting, which means the bathroom, the room where falls are most likely and cameras least acceptable, is covered by a modality that cannot produce an image. This record covers the product, not the company. Vayyar Imaging is a semiconductor business whose radar on chip platform serves automotive, smart home, retail, robotics, public safety and radio frequency testing alongside senior care, and as a whole it fails the horizontal test this index applies. Vayyar Care is a distinct product line with its own integrations, its own regulatory compliance and its own named deployments, and it is indexed here on the same basis that a diagnostic product line was separated from its parent elsewhere in this index. The technical disclosure is better than the lane norm in two specific ways. The underlying chip is specified publicly, covering imaging and radar bands from 3 to 81 gigahertz with up to 72 transceivers and an integrated digital signal processor. And coverage is published as a number rather than a claim: 13 feet to the front and 6 feet 6 inches to either side, with an explicit statement that large rooms may require more than one device. A vendor that publishes the limit of its own sensor, and says plainly when one will not be enough, has disclosed something that costs it. Distribution runs through the systems care staff already use. Named production integrations include TekTone Tek-CARE and Austco Tacera nurse call platforms, K4Connect K4Community, TLS Evolve and SenSights.AI, with the company stating interoperability with any nurse call system and care platform. Austco alone carries it across Australia, the United Kingdom, Canada and the United States. A consumer route exists through an Amazon subscription integration, and because that depends on a third party service a buyer should confirm current availability. Field deployment is real and multinational. Essex County Council reported eliminating hospital admissions and long lies from one of the largest single installations of this technology in January 2026, a United Kingdom care home published a resident safety case study in April 2026, and an Ontario long term care provider piloted 122 units. A partnership with TLS dating to 2018 is described as having detected hundreds of real falls. Two regulatory facts are stated and worth carrying. The device is described as fully approved by the United States communications regulator, which is the spectrum authorisation an emitting device in a dwelling requires, and the platform achieved the DCB0129 clinical safety standard in January 2026, the United Kingdom clinical risk management standard for health technology manufacturers. Vayyar Care makes no vital signs claim, which keeps it clear of the device boundary that other radar vendors in this lane approach. Vayyar Imaging was founded in 2011 by Raviv Melamed, Miri Ratner and Naftali Chayat, originally to detect early stage breast cancer using radio frequency, and has raised more than 300 million dollars including a 108 million dollar Series E in 2022 led by Koch Disruptive Technologies. Reporting in 2024 described layoffs and a narrowing of focus to smart home and automotive; the senior care line has continued shipping, integrating and certifying through 2026 regardless, and a buyer should read those two facts together rather than either alone.

Cherish Health detects falls and vital signs by bouncing radar off people, with no camera and nothing worn. Cherish Serenity is a device shaped like an old transistor radio that sits in the corner of a room and senses through walls, covering multiple rooms and multiple people from a single unit. Cherish AI runs at the edge, on the device itself, classifying what the radar returns into body position, movement, falls, heart rate and respiration. The discrimination problem is the interesting part of the engineering. A person lowering themselves to the floor deliberately and a person falling produce similar endpoints, and the company states its models separate them by reading body position through the descent. It also claims to catch the harder case, a fall where someone grabbed a table on the way down, which an accelerometer in a wearable would miss because the deceleration never happens. The most aggressive sensing claim is that heart rate and respiration can be read from 40 feet away through two walls with nothing worn, described by the chief executive as demonstrated in the company's own laboratory rather than published. The privacy argument is the commercial argument. Radar produces no image, so nothing resembling video of a person in a bedroom or bathroom ever exists, and edge inference means classification happens on the device. Industry coverage of the category notes that older adults are frequently unwilling to accept in home cameras, and this product is positioned directly at that refusal. Distribution runs through partners rather than a direct sales force. AT&T supplies cellular connectivity as the default, with first responder network capability, Alarm.com carries the Serenity Enterprise Hub to its service provider network for facility deployments, and security dealers including ADT sell and install to consumers. A partnership with Health eVillages placed devices at a Massachusetts veterans centre, and a senior care offering with Aileen was announced at HIMSS in March 2026. Founded in 2020 by Sumit Nagpal and Mike Sutcliff and based in Boston. Roughly 26 million dollars was raised in a Series A in March 2024 from angel and undisclosed investors, notable because the company has publicly stated it took no venture capital, and a larger second round was reported as planned. Cherish Serenity launched at CES in January 2024 and won a Fast Company Innovation by Design award that year. Two cautions for a reader. Consumer pricing of roughly 250 to 300 dollars for the device plus 39 dollars monthly comes from press reporting at launch rather than a published rate card, and dealer distribution means the price a buyer actually pays may differ. Separately, several third party company databases carry materially wrong information about this company, including an incorrect founding year, a competitor set drawn from robotic exoskeletons, and in one case an assertion that the company is publicly listed on a foreign exchange. None of it informed this record.

CarePredict infers what an older adult is doing from how their wrist moves, and raises an alert when the pattern changes. The Tempo wearable carries a motion sensor for gesture recognition alongside heart rate and pulse oximetry, and machine learning classifies activities of daily living from it: eating, drinking, bathing, grooming, tooth brushing, toilet use, walking, sitting and sleeping. Peel and stick Context beacons add room level indoor location, so the system knows not only that someone is washing but where. The models take roughly seven days to learn an individual's normal pattern, after which deviation from that personal baseline is the signal. The headline claims are early detection ones. The company states it can surface a urinary tract infection up to 3.7 days before clinical diagnosis and depression around two weeks ahead, by reading changes such as reduced eating, increased bathroom use or decreased mobility. Falls, malnutrition and elopement risk are addressed by the same behavioural layer. A substantial part of what is deployed is not predictive at all. Tempo also serves as a resident call device with two way voice, fall detection, wander management, real time location and keyless door entry by radio frequency identification, and integrators describe the system as a next generation emergency call platform. A PinPoint tool uses retained location history for contact tracing, and a TouchPoint application gives family members a real time view of a relative's activity. Vital signs are captured from separate third party cleared devices and uploaded to the dashboard or a record system, so the accuracy of those readings belongs to those devices rather than to CarePredict. Buyers are senior living operators across assisted living, memory care and independent living, home care agencies, and families buying directly for a relative aging in place. Named communities include Grand Retirement, Spring Creek Enterprise, SRI Management, Tradition Senior Living and Bickford Senior Living. Distribution extends to Canada through a reseller. Founded by Satish Movva and based in Fort Lauderdale, Florida. A 9.5 million dollar round was reported in 2019 and no subsequent raise was located, though the storefront, the reseller channel and a hardware partner case study dated December 2025 all indicate continuing operation. The Tempo wearable itself is built by NEXA Mobility, which is named publicly as the hardware partner. Pricing is more open than almost anything else in this index. The direct storefront publishes 69.99 dollars per month for the consumer at home subscription with a 45 day trial and no annual contract, and the Canadian reseller lists a two person annual package at 138 dollars per month. Enterprise senior living pricing, including the beacon infrastructure a building requires, is not published anywhere. Two cautions for a reader. Marketing carried on distributor pages states fall reduction of 69 percent and length of stay increase of 67 percent with no method, sample or citation attached, and those figures should be treated as unsupported until sourced. Separately, several third party company profiles of CarePredict circulating online contain precise sounding operational statistics that trace to no primary source and appear to be machine generated; none of them informed this record.

Canary Speech sells the model rather than the application. Its vocal biomarker engine extracts roughly 2,590 acoustic and linguistic features from the human voice every 10 milliseconds and returns behavioral and cognitive indicators from as little as 20 to 45 seconds of natural speech, delivered through an API that other products embed. Canary Ambient is the API first real time offering, running on patient and clinician conversations, with a continuous monitoring variant added subsequently. Canary Cognitive addresses the cognitive side. Because the analysis reads how someone speaks rather than what they say, the company describes the approach as language agnostic and device agnostic, workable on anything with a microphone. The published evidence is unusual in this lane for what it admits. A 2026 paper in the Proceedings of Artificial Intelligence in Medicine reports unweighted average recall of 0.70 for depression and 0.68 for anxiety, with a combined behavioral health assessment reaching sensitivity of 0.76 and specificity of 0.65 on a remote test set, and sensitivity of 0.68 with specificity of 0.80 on an independent in clinic dataset collected by tablet. Those are moderate numbers and the company published them anyway, at an operating point, which almost no competitor here does. The same work introduces an uncertain classification that flags low confidence predictions near the decision boundary rather than forcing a call, which is a deliberate clinical safety choice rather than a performance figure. Markets span health systems, payers, pharmaceutical and clinical trial work, employers, telehealth and clinical call centres. In February 2026 the company partnered with Intermountain Ventures on an institutional review board approved study led by a neurologist at Intermountain Health, testing whether vocal features can identify multiple sclerosis. That same month it entered consumer health through JubileeTV, embedding passive speech analysis into video calls between older adults and their families, its first deployment outside clinical and research settings, producing indicators the company is careful to describe as nondiagnostic. Founded in 2017 in Provo, Utah by Henry O'Connell, who began his career at the National Institutes of Health in a neurological disease group before a long medical device career, and Jeff Adams, a speech recognition specialist. Roughly 22.35 million dollars raised in total, including a 13 million dollar Series A in June 2024 led by Cortes Capital and a further round in January 2025. Investors include Sorenson Communications, SMK Corporation, Plug and Play Japan and Hackensack Meridian Health, the last of which is a health system and therefore a party whose commercial and investment interests a buyer should hold separately when weighing any reference from it. One disclosure detail deserves attention before a security review. The company's security page lists an extensive set of assurance programs covering the SOC family, FedRAMP, FISMA and four ISO standards, and attributes them accurately to the cloud partners it builds on rather than claiming them. Canary's own stated position is HIPAA compliance, control audit against a recognised benchmark, vulnerability scanning and cleared API penetration testing. No attestation held by Canary itself was located. The wording is honest; the visual effect of the list is not, and a buyer skimming it may credit the company with certifications it does not hold.

Aiberry runs a bot administered interview and scores mental health from how a person answers it. A digital animated assistant called Botberry asks open questions, the person replies in their own words on camera, and an ensemble of machine learning models reads text, audio and video together to produce a depression risk score, symptom level insight across mood, concentration and energy, and a transcript of every response. The design intent is to replace the multiple choice self rating form, where a person picks the answer that best describes them, with something closer to a conversation. Two products are sold. Digital MindCare is anonymous and login free, aimed at schools, employers and community health organisations, and collects no account or identified health record. Smart MindCare, also presented as SmartAI MindCare, is the account based clinical product where personal and health information is collected and results land in a portal for a clinician. Four buyer settings are named: corrections, corporate wellness, behavioral health and recovery, and higher education. The evidence position rests on a single peer reviewed study, and it needs reading carefully. The paper appeared in the Journal of Affective Disorders in 2024, led from the University of Texas at Austin with the Georgetown University Medical Center and the University of Arizona, covering nearly 400 participants aged 18 to 74 who completed both a Botberry interview and a gold standard depression questionnaire. It reported performance comparable to the questionnaire and found no evidence of bias by gender, age or race. Press coverage presents this as an independent university validation. The paper's own declarations state that it was funded by Aiberry, that two authors are employed by Aiberry including the author credited with conceptualisation, methodology, formal analysis and supervision, and that a third is an Aiberry research coordinator. The disclosure is properly made in the journal. The framing built around it in press material is what diverges. A second currency problem sits beside it. The company research page still links a preprint rather than the published paper, so a reader following the vendor's own citation lands on the unreviewed version of work that has since cleared review. Based in Seattle and led by co chief executives Linda Chung and Johan Bjorklund with founding scientist Newton Howard. An 8 million dollar seed round led by Confluence Capital Group with Ascension AI participating was announced in March 2023. Named collaborators include Georgetown University, the University of Arizona and Advocate Aurora Health. Disclosure outside the clinical study is thin, and a buyer should expect to establish most of it privately. A dedicated pass located no security page, no external security attestation, no trust center, no named record system integration, no hosting or data residency statement, and no pricing of any kind. The company news feed has not been updated since 2023 and no funding round after the 2023 seed was located, so commercial trajectory cannot be established from public material in either direction.

Videra Health builds multimodal artificial intelligence for behavioral health, analysing what a patient says, how they say it, and how they look while saying it. The platform sends asynchronous video, voice or text check ins that patients complete on their own devices in roughly three minutes, and scores them against established clinical instruments. Three model families work together: language models reading transcribed speech for markers such as absolutist phrasing, word complexity and sentiment; acoustic models extracting speech rate, pause duration, pitch variation and articulation; and computer vision models reading facial movement, microexpressions and affective state. The company publishes a model table, which is rare in this index. Five named models each carry a clinical application, a reported area under the curve and a modality: PHQ-V for depression screening at 0.88 to 0.90, GAD-V for anxiety at 0.90, PCL-V for post traumatic stress at 0.85 to 0.90, EPDS-V for postpartum depression at 0.89, and a video model for tardive dyskinesia at 0.87 to 0.92. The video instruments were developed in house as video native versions of the standard written scales by the co founder and chief clinical officer. The product line spans the patient journey rather than a single moment. Front Door answers inbound patient inquiries around the clock and captures scheduling preferences, Intake Accelerator moves clinical history and paperwork to the patient's own time, Assess runs continuous check ins between and after visits, Sidekick Notes documents sessions ambiently, Group Notes documents group therapy while separating individual patient voices, and Sidekick Elevate returns communication pattern data to clinicians as coaching. A separate life sciences line applies the same capture infrastructure to clinical trials and post market studies. TDScreen, a tardive dyskinesia screening tool, is offered free to any provider or patient. Reported scale is more than 300 facilities and over one million patient interactions, with more than 100,000 notes generated and a claimed 94 percent completion rate on assessments. Named deployments include Discovery Behavioral Health, which launched a platform called Discovery365 in collaboration with Videra and Brigham and Women's Hospital, and work through the Medical Technology Enterprise Consortium aimed at preventing suicide related deaths among service members. Integrations are named with Kipu, Alleva, BestNotes, BlueStep, Zoom, Epic and Cerner. Academic collaborations are stated with the University of Utah and the University of Texas. Founded in 2019 in Orem, Utah. Roughly 8.6 million dollars is disclosed across a 3 million dollar seed in 2021 and a 5.6 million dollar second seed in May 2024, both led by Peterson Ventures, with Mercato Partners, Epic Ventures, Philo Ventures, Rose Park Advisors and OATV also named. Two cautions belong on the face of this record. The company describes itself as FDA registered and displays that phrase as a badge alongside its HIPAA and security marks. Establishment registration and device listing is a filing obligation, not a review of safety or effectiveness, and it is neither clearance nor approval. No clearance was located for any product. Separately, all five peer reviewed publications are authored by company staff, and the named scientific advisor is a co author on both tardive dyskinesia papers, so the evidence base is genuine, published and internally generated rather than independently replicated.

End to end cloud platform for home and community based care, spanning needs assessment, care planning, clinical documentation, scheduling and route optimisation, visit verification, billing, family portals, remote patient monitoring, telehealth and mobile care worker applications. Founded 2014 by Adrian Schauer, who won a national entrepreneur award in 2025. Roughly 608 staff as of February 2026. Sources disagree on headquarters, giving Toronto and Montreal, with a United States entity registered in Boston. Market coverage is unusually specific and genuinely international. The platform is sold across Canada, the United States and Australia, into private duty nursing and non skilled care, Medicaid, community support services, therapy, patient support programmes, clinical pharmacy, hospice, home infusion, and Australian aged care including consumer directed care and the national disability scheme. That last is a country specific programme rather than a generic claim to international availability. The artificial intelligence sits on top of the platform rather than being it. A dedicated research group develops the capability, which covers predictive analytics flagging clients at risk before escalation, clinical documentation extraction, travel time reduction, an employee retention dashboard, and back office automation. Two named products carry it: Layla, an assistant launched in Canada in June 2025, and AlayaFlow, agentic workflow automation launched in October 2025. The company claims agencies reclaim 80 percent of time and costs through the newer automation, a figure published in March 2026 and unsupported by any study located. Trust posture is stronger than most records in this index. A trust centre exists as a named destination, the platform is stated to meet four named privacy frameworks across two countries and to pass regular controls audits at the more demanding report type, with the original certification audited by a named accounting firm in 2020. Infrastructure runs on a named public cloud with data sovereignty cited as a design consideration across the three markets. The finding worth flagging is on governance. The company publicly references its signatory status under a national voluntary code of conduct for advanced generative artificial intelligence systems, which is the first verifiable artificial intelligence governance credential recorded anywhere in this index. It is a commitment framework rather than published evidence, and it is more than any competitor offers. No pricing is published by the vendor. Third party software directories estimate entry cost around 1,000 dollars per month scaling with practitioner count, modules, integrations and training, and one explicitly rates the company's pricing transparency as low. Those are estimates rather than disclosure and are recorded as such. Named customers include CBI Home Health, which renewed nationally in June 2025, and a group of 33 community support agencies modernised in August 2025. Financing includes a 50 million dollar growth capital facility from a Canadian bank in February 2026.

Callyope is a Paris company building an audio and language foundation model trained specifically on psychiatric data rather than adapted from a general purpose speech model. Patients use a smartphone application for voice journals, short structured speech tasks, symptom self reports, or passive analysis of calls with designated caregivers, and the model combines that speech with smartphone sensor signals covering sleep and activity and with clinical information to produce continuous symptom scores between appointments. The clinician side adds case summarisation from uploaded records, consultation notes, referral and hospitalisation documents, and identification of gaps in medical coding. The founding team is a research team: Rachid Riad completed a doctorate at the Ecole Normale Superieure on automatic assessment of cognitive, linguistic and emotional disorders affecting speech in Huntington disease, and the company publishes at speech science venues, including two papers at Odyssey 2026, one on learning health related speech representations and one on approximate signal processing as a route toward homomorphic encryption for audio. A registered trial of voice based biomarkers for predicting schizophrenia relapse is running with an estimated 200 participants and completes in October 2026.

Biobeat sells wearable continuous vital sign monitors and a cloud platform, and its position in this category is distinctive: where other vendors build models on data that already exists, Biobeat changes what data exists in the first place. Its answer to the ward monitoring problem is to make ward patients continuously monitored rather than measured every few hours. The hardware is a disposable chest patch and a wrist worn device, both built on a proprietary reflective photoplethysmography sensor. From that single optical signal the company derives a set of parameters that has expanded through successive FDA clearances: cuffless blood pressure, blood oxygen saturation and pulse rate cleared in August 2019, respiratory rate and body temperature added in March 2022, and stroke volume and cardiac output added in October 2024. Biobeat states these were the first devices cleared by the FDA for cuffless blood pressure monitoring derived from photoplethysmography alone. The devices also carry CE marking and the company holds MDSAP certification. Data transmits to a cloud platform for viewing by clinical staff, with integration into the hospital EMR. On top of the measurements sits an automated real time early warning score which the company describes as incorporating advanced AI based algorithms to alert on patient status and potential deterioration. The FDA clearances cover the measurement of physiological parameters; nothing retrieved indicates the early warning score itself is cleared, and a buyer should establish that distinction directly. Marketed settings span general wards, surgical wards, post surgical recovery, step down and medical surgical units, intensive care and emergency departments, alongside ambulatory blood pressure monitoring, nursing homes and hospital at home programmes. The chest patch is also used for 24 hour ambulatory monitoring with automated report generation. Biobeat was founded in 2016, is headquartered in Petah Tikva, Israel, and is led by founder and chief executive Arik Ben Ishay. International distribution agreements include partners in the Dominican Republic, Argentina and Chile. Pricing is not published.

VieCure sells Halo Intelligence, a combined clinical decision support system and oncology electronic medical record built specifically for community cancer care rather than academic centres. The platform generates and monitors personalised treatment plans from diagnosis through therapy and survivorship, drawing on patient data, physician notes, imaging, labs, next generation sequencing, molecular pathology and treatment response, and spanning medical, radiation and surgical oncology. The mechanism matters and the company describes it plainly. Recommendations come from a clinical inference engine reasoning over a codified content library the company reports at more than 5,000 clinical rules, covering treatment plans, pathways, protocols, drug and toxicity management, payer rules, trial eligibility criteria, diagnostics and formularies. In 2025 VieCure signed a non exclusive licensing agreement with the National Comprehensive Cancer Network, adding NCCN template based treatment plans to the platform, so a substantial part of the knowledge base is traceable to the authoritative published guideline body in oncology. Founded in Denver and launched in 2016. A 45 million dollar financing led by Northpond Ventures closed in October 2024, alongside the appointment of Richard Daly as board chairman. The company reports more than 18,000 patients managed daily across a community cancer centre network exceeding 100 locations, with named users including American Oncology Network, The Oncology Institute, Oncology Care Partners and Summit Cancer Centers. Not a surgical decision support product. It covers surgical oncology as one discipline within a cancer care platform whose buyer is a community oncology practice.

Digital cognitive screening built for population scale deployment inside health system workflows rather than for depth of assessment, which is the strategic difference from others in this category. The core product is a three minute patient-guided test producing instant objective scoring with DSM-5 aligned output, deliberately sized to fit inside a Medicare Annual Wellness Visit without adding clinician burden or requiring specialised training to administer. The company positions cognitive function as something to be checked routinely like a vital sign, targeting the detection gap it cites where roughly 80 percent of adults aged 65 to 80 receive no routine cognitive screening. Founded 2012 by Elli Kaplan with academic co-founders including Elizabeth Buffalo and cognitive impairment researcher Stuart Zola, with leadership backgrounds at UCSD, the Atlanta VA Medical Center and Emory. Reports 25 peer reviewed papers, 11 patents, FDA Class II registration, more than $62.8 million in venture funding plus $4.3 million in grants from the National Institute on Aging, the Alzheimer's Drug Discovery Foundation and the Georgia Research Alliance, and over 200,000 assessments delivered. Named health system customers include Sutter Health, Providence and Stanford Medicine, with reported reach across more than 15,000 clinicians. An important historical correction the company makes itself and which older coverage gets wrong: Neurotrack originated in eye-tracking based cognitive assessment, and much third party writing still describes it that way, but the company states plainly that while digital eye tracking was among its first technologies it is not part of its current clinician product suite, which now uses patient-led tests selected for validity, accessibility and ease of administration. Tests use culturally agnostic symbols and numbers by design. Also supports RADV audit documentation and Medicare Advantage quality workflows.

Digital musculoskeletal clinic pairing computer vision motion tracking with a clinical care team of physicians, physical therapists, nurses and health coaches. NYSE listed as HNGE. The technology core is genuinely substantial rather than a wrapper: the company acquired wrnch in 2021, the developer of a leading computer vision platform for measuring human motion using the same class of three-dimensional tracking employed in elite sport and motion capture for film, and stated at the time that the acquisition gave it the largest computer vision team in digital health. That became TrueMotion, which turns an ordinary smartphone camera into a 3D motion assessment tool, detecting 87 reference points across the body with no specialised equipment, and provides live audio and visual feedback on exercise form. In October 2025 the company launched Movement Analysis, which uses TrueMotion to capture joint angles, symmetry and endurance and combines those objective measures with questionnaires to produce HingeScore, plus Robin, an AI care assistant for members. It also published a set of AI care principles governing development across the platform. The strategic argument is worth understanding: almost all established MSK outcome measures rely on patient self-report, so an objective movement measurement captured at home is a genuine measurement contribution rather than a workflow convenience. The company also sells Enso, an FDA cleared wearable delivering electrical nerve stimulation for pain relief. Serves self-insured employers and health plans at large scale. Indexed with a clear scoping note: this is a care delivery organisation with a strong technology layer, not a software vendor, and the AI is graded on that basis. Sits alongside Sword Health, its closest competitor, also indexed.

Digital cognitive assessment and care planning platform. The flagship product, BrainCheck Assess, is a Class II FDA regulated device that delivers a standardized battery of digital cognitive tasks covering memory, executive function, attention, mental flexibility and processing speed, drawn from digital versions of established neuropsychological instruments including Stroop, Trail Making and Digit Symbol Substitution. It sits within a wider platform of more than 30 clinical evaluation tools, screeners and care planning instruments that clinicians can combine into custom protocols. Co-founded by neuroscientist David Eagleman. More than 400,000 cognitive assessments have been completed on the platform. The evidence base is comparatively strong and is published rather than asserted: a validation study of 99 participants reported at least 88 percent sensitivity and specificity separating normal cognition from dementia and at least 77 percent separating mild cognitive impairment from the other groups; a later study found a Pearson correlation of 0.77 against the Montreal Cognitive Assessment; and a 529 participant multi-site study conducted with BrainBox Solutions and registered as NCT04423198 assessed test retest reliability and concurrent validity against traditional paper and pencil tests. Remote self-administration has been reported as statistically indistinguishable from in-person coordinator led sessions. Important scoping note: the AI content of this product is limited. The battery is a digitized and normed set of conventional neuropsychological tests with an expanding normative database, not a machine learning diagnostic model, and the company states the platform is not intended as a stand-alone diagnostic tool and is designed to support clinician interpretation rather than replace it. Indexed for the assessment platform, and graded accordingly on AI Centrality.

South Korean medical AI company whose flagship DeepCARS predicts in-hospital cardiac arrest within 24 hours for patients in general wards, using only four routinely collected vital signs drawn from the EMR: blood pressure, heart rate, respiratory rate, and temperature. Distinctive in this index for operating on biosignals rather than images, in a market where Korean medical AI was largely image based, and for the deployment scale it has reached in one national system, more than 48,000 hospital beds across South Korea including 20 tertiary general hospitals. Approved by Korea's MFDS in 2021 and holding US FDA Breakthrough Device Designation since 2023 while pursuing 510(k) clearance.

Point of care EEG company combining a rapidly deployable headband with the Clarity machine learning algorithm, which interprets EEG every ten seconds across all channels to produce a seizure burden estimate and alert bedside clinicians to suspected status epilepticus. Designed for emergency departments and intensive care units where conventional EEG and neurology interpretation are not immediately available. Publicly traded, and the only AI point of care EEG cleared across the full age range from preterm neonates through adults.

ECG led diagnostics software company whose AccurECG Analysis System is an FDA cleared Class II Software as a Medical Device for fully automated, near real time ECG interpretation. The platform is device agnostic, ingesting data from patches, Holter monitors, and telemetry devices, and performs beat by beat analysis, ectopic beat detection, heart rate measurement, and automated interpretation of thirteen rhythm classifications. A pipeline of ECG derived biomarkers is in development under FDA Breakthrough Device Designation.

AI enabled value based care enablement platform for health systems and clinically integrated networks, combining a proprietary predictive model with virtually embedded Healthguides, medical assistants trained in data science who work under licensed clinical supervision to extend care team reach. The platform identifies high risk patients, coordinates referrals and prior authorization, and supports performance in risk based contracts. Formed in 2023 and built partly on the acquired value based care services division of an analytics vendor.

Respiratory diagnostics company developing Sylvee, a chest worn wearable that uses patented active acoustic resonance, projecting low frequency sound into the lungs and analyzing the returning signal with machine learning, to measure lung structure and function. Positioned to replace effort dependent spirometry with a passive test and to enable continuous home monitoring for COPD and small airway disease. Backed in part by NIH small business funding; the device is investigational and not FDA cleared.

Voice AI care management for health plans and at risk providers, originating in vocal biomarker research for detecting depression and anxiety and now productized as Sage, an AI care manager. The distinguishing technical claim is the Empathy Engine, patented vocal biomarker technology trained on millions of live clinical patient calls, which reads emotional state from voice in real time rather than only transcribing words, and adapts tone and approach accordingly. Sage conducts inbound and outbound member calls covering health risk assessments, post discharge follow up, risk profiling, care gap closure, program enrollment, medication reminders, and triage, and is positioned explicitly as added staffing capacity rather than a chatbot, reserving clinicians for complex high touch interventions. Integrations include Salesforce Health Cloud and, through an April 2026 partnership with HealthEdge, the Care Solutions suite drawing on GuidingCare member data and returning outcomes to the platform. Company reported figures, which it acknowledges are not independently audited, include roughly 60 percent reduction in administrative tasks, 6x faster program enrollment, and 4x return on investment. Named customers per the company website include UnitedHealth Group, Aetna, Duke Health, and Highmark. Founded 2017 by CEO Mainul Mondal; approximately $75 million raised including a $45 million round in June 2025 co-led by Salesforce, Khosla Ventures, and CVS Health Ventures.

Inpatient virtual care platform, and the first vendor in this index covering AI assisted virtual nursing and virtual sitting inside the hospital rather than in the home. The platform is modular: AI Assisted Virtual Nursing supporting virtual rounding, admissions, and discharges; AI Assisted Virtual Sitting and Patient Safety Monitoring, where the AI models cover fall prevention, fall detection, and pressure injury prevention; plus ambient documentation, patient engagement, digital whiteboards and room signage, hospital at home, remote patient monitoring, and a digital clinic. Hardware is part of the offering, including smart carts and in wall fixed devices providing video in the patient room. The stated design intent is extending clinical capacity rather than replacing staff: continuous monitoring across multiple units simultaneously so a smaller number of nurses can observe more rooms and intervene earlier. Reported adoption grew from more than 70 US health systems in February 2026 to more than 100 by June 2026. Named enterprise deployments include Ardent Health (NYSE: ARDT) across more than 2,000 patient rooms, MultiCare Health System as its enterprise virtual care platform, and One Brooklyn Health. Headquartered in Clearwater, Florida.

Audio based AI monitoring for home care and senior living, and the third distinct sensing architecture in this lane. Small audio pods placed through a residence listen for verbal and non verbal cues rather than using cameras, a deliberate choice the founder attributes to cameras feeling intrusive in the home. The Care Agent continuously detects and predicts care events across physical, cognitive, and emotional wellbeing, and the company reports identifying more than 100 distinct insights, extending well past emergencies: alongside falls it flags possible urinary tract infections, pneumonia, early signs of cognitive decline, and softer signals including changes in activity level, sentiment, and lack of companionship. A clinical team including a social worker, occupational therapist, nurses, and geriatrics clinicians develops new data points on an ongoing basis. The platform has expanded beyond monitoring into agency operations with a Growth Agent handling inbound demand and an Ops Agent covering scheduling, callouts, and communication. The company reports serving 80 percent of the largest home care networks in North America and revenue tripling year over year for three consecutive years. Founded 2019 by Romi Gubes; $45 million Series C in October 2025 led by Qumra Capital brought total funding above $98 million.

Clinician led transitional care focused on the high risk window after hospital discharge, sold to health systems and payors as a clinical service line rather than as software alone. The proprietary clinical AI, AiME, was built by clinicians and grounded in physician validated protocols: it engages patients in real time, interprets symptoms against the individual's medical history, medications, and comorbidities, continuously detects emerging risk signals, and escalates to a dedicated Transitionist, a licensed clinician who owns the episode of care from discharge through recovery. The model pairs an AI front door with a physician led practice, adding AI assisted care plans, documentation, and billing plus omnichannel round the clock patient support. The company is credited with large reductions in avoidable readmissions. As with several vendors in this category, buyers should evaluate the AI and the care delivery operation as two distinct things: what is being purchased is a staffed clinical service accelerated by AI, not a platform. Founded 2023; $13.5 million Series A in March 2026 led by Team8 and Table Management, bringing total funding to nearly $20 million.

AI care platform sold to self insured employers and health plans, indexed for those business to business products rather than the direct to consumer application launched in 2026, which is outside the scope of this record. Phoenix, the company's AI care specialist, delivers real time motion biofeedback and around the clock natural language support, paired with a licensed clinician who remains in the loop for every member: Doctors of Physical Therapy in the musculoskeletal programs, with specialist type varying by product. Thrive covers musculoskeletal care through digital physical therapy with a motion tracking device, and the line has extended into women's health (Bloom) and cardiometabolic care (Pulse, announced for later 2026 with outcomes based pricing and connected device integration). The company reports more than 800,000 members served, 11 million AI care sessions, over 1,000 clients including a fifth of the Fortune 500, and customer avoided costs exceeding $1 billion, alongside per member savings of $3,177 a year for the musculoskeletal program. Founded 2015 by Virgilio Bento; valued at $3 billion following a 2024 round led by Khosla Ventures and General Catalyst.

Precision health technology company, indexed here for its business to business products rather than its consumer app. Lightpath is an AI enabled chronic care management program sold to health plans, employers, and pharmacy benefit managers, using agents to triage and escalate members to a clinical team of physicians, pharmacists, and dietitians, with Lightpath Metabolic covering diabetes, prediabetes, and obesity. Workbench is a research data environment used by the NIH All of Us Research Program, the Michael J. Fox Foundation, and Helix. Sightline is a wastewater based epidemiology program for early infectious disease detection. The free Verily Me consumer application is outside the scope of this record. Formerly an Alphabet subsidiary; became an independent company in March 2026 alongside a $300 million investment round.

AI enabled chronic care management for older adults: supervised AI agents monitor daily vitals from connected devices, surface risk between visits, and coordinate clinical action for patients with hypertension, type 2 diabetes, heart failure, and COPD. Operates in partnership with more than 20 health systems with an embedded medical group, and reports 55 percent of vitals alerts resolved autonomously with a 3.5 minute median response time.